SCICLONE PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|---|---|
| Revenue | $160.1M | $157.3M | $134.8M | $127.1M | $156.3M | $132.6M |
| Operating income | $33.2M | $29.9M | $26.0M | $10.4M | $6.4M | $29.0M |
| Net income | $7.9M | $9.0M | $25.2M | $4.2M | $9.7M | $28.1M |
| Total assets | $241.9M | $216.6M | $181.8M | $180.2M | $174.1M | $200.8M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $215.4M | $179.7M | $155.3M | $146.6M | $143.0M | $150.1M |
| EPS (diluted) | $0.15 | $0.17 | $0.48 | $0.08 | $0.16 | $0.49 |
| Shares out. | 49.6M | 50.1M | 52.0M | 54.0M | 57.8M | 57.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- 20.8%
- Net margin
- 4.9%
- Return on equity
- 3.7%
- Return on assets
- 3.3%
- Return on capital (ROCE)
- 15.4%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $4.34
- Revenue growth (YoY)
- 1.8%
- Net income growth (YoY)
- −12.3%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Accruals / assets
- −11.0%clean
- Piotroski F-Score
- 6/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 13, 2013
- NT 10-Kmissed a reporting deadline ↗Mar 14, 2013
- NT 10-Kmissed a reporting deadline ↗Mar 17, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Blobel FriedhelmOfficer — President, CEO, Director | Oct 13, 2017 | Option exercise | 95,000 | — |
| Saxe Jon SDirector | Oct 13, 2017 | D | 135,000 | $11.18 |
| Low Raymond AnthonyOfficer — VP, Finance & Controller | Oct 13, 2017 | Option exercise | 11,250 | — |
| Zhao HongOfficer — CEO, China Operations | Oct 13, 2017 | Option exercise | 52,000 | — |
| Chang Nancy TDirector | Oct 13, 2017 | D | 70,000 | $11.18 |
| Chern CareyOfficer — General Counsel | Oct 13, 2017 | Option exercise | 30,000 | — |
| Xie LanOfficer — VP Finance, China CFO | Oct 13, 2017 | Option exercise | 8,000 | — |
| Hawkins Richard JDirector | Oct 13, 2017 | D | 24,363 | $11.18 |
| Cheung Wilson Wai-ShunOfficer — CFO & Senior VP, Finance | Oct 13, 2017 | Option exercise | 52,000 | — |
| Zhao HongOfficer — CEO, China Operations | Aug 15, 2017 | Option exercise | 30,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 13, 2017
- Shareholder voteSep 27, 2017
- Other material eventAug 10, 2017
- Results of operationsAug 9, 2017
- Other material eventJun 23, 2017
- Shareholder voteJun 9, 2017
- Entered a material agreement · Other material eventJun 8, 2017
- Results of operationsMay 10, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.